Improving Early Drug Discovery through ADME Modelling

Drug development is an intrinsically risky business. Like a high stakes poker game the entry costs are high and the probability of winning is low. Indeed, only a tiny percentage of lead compounds ever reach US FDA approval. At any point during the drug development process a prospective drug lead may be terminated owing to lack of efficacy, adverse effects, excessive toxicity, poor absorption or poor clearance. Unfortunately, the more promising a drug lead appears to be, the more costly it is to terminate its development. Typically, the cost of killing a drug grows exponentially as a drug lead moves further down the development pipeline. As a result there is considerable interest in developing either experimental or computational methods that can identify potentially problematic drug leads at the earliest stages in their development. One promising route is through the prediction or modelling of ADME (absorption, distribution, metabolism and excretion). ADME data, whether experimentally measured or computationally predicted, provide key insights into how a drug will ultimately be treated or accepted by the body. So while a drug lead may exhibit phenomenal efficacy in vitro, poor ADME results will almost invariably terminate its development. This review focuses on the use of ADME modelling to reduce late-stage attrition in drug discovery programmes. It also highlights what tools exist today for visualising and predicting ADME data, what tools need to be developed, and the importance of integrating ADME data to aid in compound selection during the earliest phases of drug discovery. In particular, it highlights what tools exist today for visualising and predicting ADME data including: (1) ADME parameter predictors; (2) metabolic fate predictors; (3) metabolic stability predictors; (4) cytochrome P450 substrate predictors; and (5) physiology-based pharmacokinetic (PBPK) modelling software. It also discusses what kinds of tools need to be developed, and the importance of integrating ADME data to aid in compound selection during the earliest phases of drug discovery.

[1]  Igor V Tetko,et al.  The WWW as a tool to obtain molecular parameters. , 2003, Mini reviews in medicinal chemistry.

[2]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[3]  G Beck,et al.  Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. , 2001, Journal of pharmaceutical sciences.

[4]  Kathleen F. Kerr,et al.  Evaluation of methods for oligonucleotide array data via quantitative real-time PCR , 2006, BMC Bioinformatics.

[5]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[6]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[7]  A. Nomeir,et al.  Utility of mass spectrometry for in-vitro ADME assays. , 2006, Current drug metabolism.

[8]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[9]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[10]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[11]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[12]  David S. Wishart,et al.  Applications of Machine Learning in Cancer Prediction and Prognosis , 2006, Cancer informatics.

[13]  Prabha Garg,et al.  In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..

[14]  Gabriele Cruciani,et al.  QSAR study and VolSurf characterization of anti-HIV quinolone library , 2001, J. Comput. Aided Mol. Des..

[15]  Richard Svensson,et al.  Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. , 2006, Pharmacological reports : PR.

[16]  Mark Watson,et al.  Optimizing the use of open-source software applications in drug discovery. , 2006, Drug discovery today.

[17]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[18]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[19]  Leming Shi,et al.  Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators. , 2005, European journal of medicinal chemistry.

[20]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[21]  Franco Lombardo,et al.  In silico ADME prediction: data, models, facts and myths. , 2003, Mini reviews in medicinal chemistry.

[22]  Meir Glick,et al.  Enrichment of Extremely Noisy High-Throughput Screening Data Using a Naïve Bayes Classifier , 2004, Journal of biomolecular screening.

[23]  C. Selassie,et al.  QSAR: then and now. , 2002, Current topics in medicinal chemistry.

[24]  Darren V S Green,et al.  Virtual screening of virtual libraries. , 2003, Progress in medicinal chemistry.

[25]  D. Rogers,et al.  Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.

[26]  Jianzhong Liu,et al.  Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis. , 2007, Molecular pharmaceutics.

[27]  O. Pelkonen,et al.  In vitro screening of drug metabolism during drug development: can we trust the predictions? , 2005, Expert opinion on drug metabolism & toxicology.

[28]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery. 4. Prediction of Aqueous Solubility Based on Atom Contribution Approach , 2004, J. Chem. Inf. Model..

[29]  Z R Li,et al.  Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors. , 2006, Current topics in medicinal chemistry.

[30]  D. S Samiulla,et al.  Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery , 2005, Molecular Diversity.

[31]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  Narayanan Surendran,et al.  Implementation of an ADME enabling selection and visualization tool for drug discovery. , 2004, Journal of pharmaceutical sciences.

[33]  Pierre Tufféry,et al.  FAF-Drugs: free ADME/tox filtering of compound collections , 2006, Nucleic Acids Res..

[34]  A. Li,et al.  Screening for human ADME/Tox drug properties in drug discovery. , 2001, Drug discovery today.

[35]  W. L. Chiou,et al.  The Rate and Extent of Oral Bioavailability versus the Rate and Extent of Oral Absorption: Clarification and Recommendation of Terminology , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  Evi Kostenis,et al.  Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. , 2006, Journal of medicinal chemistry.

[37]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.

[38]  D. Dalvie,et al.  Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics. , 2000, Current pharmaceutical design.

[39]  C. Sensen,et al.  On the way to building an integrated computational environment for the study of developmental patterns and genetic diseases , 2006, International journal of nanomedicine.

[40]  P J Sinko,et al.  Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Les Lang.  Valdecoxib withdrawal leaves pain relief treatment gap. , 2005, Gastroenterology.

[42]  H VandeWaterbeemd.  From in vivo to in vitro/in silico ADME: progress and challenges. , 2005 .

[43]  Richard Horton,et al.  Vioxx, the implosion of Merck, and aftershocks at the FDA , 2004, The Lancet.

[44]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[45]  W. Humphreys,et al.  The use of radiolabeled compounds for ADME studies in discovery and exploratory development. , 2004, Current pharmaceutical design.

[46]  Anthony E. Klon,et al.  Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..

[47]  J. Lindon,et al.  Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.

[48]  Lawrence X. Yu,et al.  Predicting Human Oral Bioavailability of a Compound: Development of a Novel Quantitative Structure-Bioavailability Relationship , 2000, Pharmaceutical Research.

[49]  P. Snow,et al.  Introduction to artificial neural networks for physicians: Taking the lid off the black box , 2001, The Prostate.

[50]  Anthony E. Klon,et al.  Finding more needles in the haystack: A simple and efficient method for improving high-throughput docking results. , 2004, Journal of medicinal chemistry.

[51]  H. Waterbeemd,et al.  Fromin vivotoin vitro/in silicoADME: progress and challenges , 2005 .

[52]  Yi Li,et al.  In silico ADME/Tox: why models fail , 2003, J. Comput. Aided Mol. Des..

[53]  Thomas Fox,et al.  Machine learning techniques for in silico modeling of drug metabolism. , 2006, Current topics in medicinal chemistry.